menu
    • menu

    Company profile for TransCode Therapeutics

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown...
    TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for approximately 90% of all cancer deaths representing over 9 million deaths per year worldwide. We believe that TTX-MC138 has the potential to produce regression without recurrence.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TransCode TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    17 Briden Street, Worcester MA 01605
    Telephone
    Telephone
    857-837-3099
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.transcodetherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Transcode Therapeutics Appoints Jack E. Stover To Board
    Transcode Therapeutics Appoints Jack E. Stover To Board

    22 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/transcode-therapeutics-expands-leadership-with-appointment-of-jack-e-stover-to-board-of-directors-302647534.html

    PR NEWSWIRE BIO
    22 Dec 2025
    Share Share
    TransCode Therapeutics Names Janicot Senior Development Officer
    TransCode Therapeutics Names Janicot Senior Development Officer

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transcode-therapeutics-expands-executive-team-with-appointment-of-dr-michel-janicot-as-senior-development-officer-302616366.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    Transcode Therapeutics Unveils Phase 1a Results with TTX-MC138
    Transcode Therapeutics Unveils Phase 1a Results with TTX-MC138

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transcode-therapeutics-presents-preliminary-data-from-its-completed-phase-1a-study-with-ttx-mc138-in-metastatic-disease-at-esmo-302582916.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Transcode Rewrites Future, Securing $25M And Phase 3 Vaccine
    Transcode Rewrites Future, Securing $25M And Phase 3 Vaccine

    08 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/transcode-rewrites-future-securing-25m-lifeline-and-phase-3-cancer-vaccine

    FIERCE BIOTECH
    08 Oct 2025
    Share Share
    TransCode Completes Dosing in Phase 1a Trial Cohort 4
    TransCode Completes Dosing in Phase 1a Trial Cohort 4

    08 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-initial-dosing-of-patients-in-cohort-4-of-phase-1a-clinical-trial-no-dose-limiting-toxicities-reported-302449745.html

    PR NEWSWIRE
    08 May 2025
    Share Share
    TransCode Reports Progress on Phase 1a Trial in Metastatic Cancer
    TransCode Reports Progress on Phase 1a Trial in Metastatic Cancer

    01 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transcode-therapeutics-reports-further-progress-on-phase-1a-clinical-trial-with-no-dose-limiting-toxicities-reported-in-patients-with-metastatic-cancer-302443677.html

    PR NEWSWIRE
    01 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search